Biotech RadarJobs updated

COMPANY

Keros Therapeutics

HQ: Lexington, MA source · kerostx.com ↗ · New England

Clinical Phase 2

19 open jobs · last seen Oct 23, 2026 · 7 sources

Location: Lexington, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Duchenne Muscular Dystrophy Pulmonary Arterial Hypertension Iron Deficiency Anemia KER-065 KER-047

19Open jobs3Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Clinical Science Co-OpLexington, MA (Hybrid)Oct 7, 2026Oct 9, 2026
Contract Senior IT Infrastructure EngineerLexington, MA (Hybrid)Oct 6, 2026Oct 9, 2026
Contract IT Support TechnicianLexington, MA (Hybrid)Sep 28, 2026Oct 9, 2026
Senior Director, Financial Planning & AnalysisLexington, MA (Hybrid)Sep 18, 2026Oct 9, 2026
Director, Regulatory OperationsLexington, MA (Hybrid); RemoteSep 11, 2026Oct 9, 2026

See all 19 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

  1. Board tracked Radar started tracking this company’s job board (19 open jobs at last check). source ↗
  2. Trial start Phase 2: Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy source ↗
  3. Partnership Partnership / licensing announced Mar 9, 2026. Source: SEC filing. source ↗
  4. Partnership Partnership / licensing: $200M (upfront, as published), announced Jan 21, 2025. Source: SEC filing. source ↗
  5. Partnership Partnership / licensing: $200M (upfront, as published), announced Dec 3, 2024. Source: SEC filing. source ↗
  6. Trial start Phase 2: A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). source ↗
  7. Trial start Phase 2: A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 19

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Clinical Science Co-OpLexington, MA (Hybrid)Oct 7, 2026Oct 9, 2026Entry
Contract Senior IT Infrastructure EngineerLexington, MA (Hybrid)Oct 6, 2026Oct 9, 2026Senior
Contract IT Support TechnicianLexington, MA (Hybrid)Sep 28, 2026Oct 9, 2026Entry
Senior Director, Financial Planning & AnalysisLexington, MA (Hybrid)Sep 18, 2026Oct 9, 2026Senior
Director, Regulatory OperationsLexington, MA (Hybrid); RemoteSep 11, 2026Oct 9, 2026Senior
Senior Director, Process DevelopmentLexington, MA (Hybrid)Sep 10, 2026Oct 9, 2026Senior
Senior Medical DirectorLexington, MA (Hybrid)Sep 4, 2026Oct 9, 2026Senior
Upstream Process Development Co-OpLexington, Massachusetts, United StatesSep 2, 2026Oct 9, 2026Entry
Research Associate Co-Op, BioanalyticalLexington, Massachusetts, United StatesSep 2, 2026Oct 9, 2026Entry
Research Associate Co-Op, In Vivo Pharmacology Muscle and MetabolismLexington, Massachusetts, United StatesSep 1, 2026Oct 9, 2026Entry
Research Associate Co-Op, Protein BiochemistryLexington, Massachusetts, United StatesAug 31, 2026Oct 9, 2026Entry
Research Associate Co-Op, In Vivo Bone PharmacologyLexington, Massachusetts, United StatesAug 31, 2026Oct 9, 2026Entry
Research Associate Co-Op, In Vivo Pharmacology (Neuromuscular Team)Lexington, Massachusetts, United StatesAug 31, 2026Oct 9, 2026Entry
Research Associate Co-Op, In Vitro PharmacologyLexington, Massachusetts, United StatesAug 31, 2026Oct 9, 2026Entry
Downstream Process Development Co-OpLexington, Massachusetts, United StatesAug 28, 2026Oct 9, 2026Entry
Research Associate Co-Op, Protein BiochemistryLexington, Massachusetts, United StatesAug 27, 2026Oct 9, 2026Entry
Information Technology (IT) Co-OpLexington, MA (Hybrid)Aug 27, 2026Oct 9, 2026Entry
Part-Time Contract Statistical ProgrammerLexington, MA (Hybrid); RemoteJul 23, 2026Oct 9, 2026Senior
Join our Talent CommunityLexington, Massachusetts, United StatesOct 28, 2022Oct 9, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Last 2 years.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT07704099Safety and Efficacy of KER-065 in Participants With Duchenne Muscular DystrophyPhase 2RecruitingSep 25, 2026Aug 26, 2028 (estimated)
NCT05975905A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).Phase 2TerminatedOct 17, 2023Mar 5, 2025 (actual)
NCT05927012A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).Phase 2WithdrawnNov 30, 2023Aug 29, 2025 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Keros Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback